



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

February 4, 2020

National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex
Bandra (E)
Mumbai 400 051

Scrip Code : JBCHEPHARM

Dear Sir,

Sub: Outcome of the Meeting of the Board of Directors - Unaudited Financial Results for the quarter ended on December 31, 2019.

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular nos. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find

1. Standalone unaudited financial results for the quarter ended on December 31, 2019 accompanied by limited review report; and
2. Consolidated unaudited financial results for the quarter ended on December 31, 2019 accompanied by limited review report.

These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 12.00 noon and concluded at 1.20 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta

Company Secretary and Vice President - Compliance

Encl: As above

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
☎ +91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2019

Sl.No.	PART I - Particulars	Quarter ended			Nine Month ended		(Rs. in lakhs)
		12/31/2019	9/30/2019	12/31/2018	12/31/2019	12/31/2018	Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	3/31/2019 Audited
1	Revenue from Operations	38,495.45	42,812.42	35,192.83	122,387.92	112,203.93	150,118.70
2	Other Income	1,602.19	1,810.70	1,557.92	4,646.64	2,493.65	4,022.50
3	Total Income (1+2)	40,097.64	44,623.12	36,750.75	127,034.56	114,697.58	154,141.20
4	Expenses						
	a. Cost of materials consumed	9,926.20	10,619.99	11,049.81	33,163.93	33,601.07	45,375.37
	b. Purchases of stock-in-trade	2,818.88	4,497.95	2,346.28	8,682.24	7,723.59	10,426.13
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	116.46	176.96	(1,964.69)	1,299.85	(2,263.92)	(2,165.74)
	d. Employee benefit expenses	7,355.40	6,969.05	6,475.90	21,388.56	19,039.62	25,797.86
	e. Finance Costs	85.28	87.43	126.93	253.08	325.73	411.51
	f. Depreciation and amortization expense	1,654.59	1,622.32	1,448.54	4,839.82	4,341.68	5,482.49
	g. Other Expenses	9,870.20	10,471.86	10,042.28	30,142.94	31,251.70	41,886.05
	Total Expenses (4)	31,827.01	34,445.56	29,525.05	99,770.42	94,019.47	127,213.67
5	Profit before Tax (3-4)	8,270.63	10,177.56	7,225.70	27,264.14	20,678.11	26,927.53
6	Tax expenses	2,053.37	581.63	2,588.35	5,536.31	6,689.70	8,721.61
7	Net Profit after Tax for the period (5-6)	6,217.26	9,595.93	4,637.35	21,727.83	13,988.41	18,205.92
8	Other Comprehensive Income (net of Tax)	(7.63)	(252.80)	(61.80)	(265.63)	(185.41)	29.25
9	Total Comprehensive Income after Tax (7+8)	6,209.63	9,343.13	4,575.55	21,462.20	13,803.00	18,235.17
10	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	7.75	11.96	5.64	27.08	17.02	22.15
	(2) Diluted	7.75	11.96	5.64	27.08	17.02	22.15

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 4, 2020.
- The auditors have carried out limited review of the financial results for the quarter and nine months ended December 31, 2019 and their report does not contain any qualification.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Company has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the standalone financial results for the quarter and nine months ended December 31, 2019, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and nine months ended December 31, 2019 is not material. To this extent, performance for the quarter and nine months ended December 31, 2019 is not comparable with previous period results.
- The Company has completed the buy-back of 29,54,545 equity shares of Rs. 2 each @ Rs. 440 per share on January 8, 2020. Post this buy-back, the share capital of the Company stands reduced to Rs. 15,45,64,194 divided into 7,72,82,097 equity shares of Rs. 2 each.
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

S.B. Mody

Whole time Director (Marketing)

Place : Mumbai
Date : 04/02/2020

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380

Independent Auditor's Review Report on Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2019 of the J. B. Chemicals & Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
J. B. Chemicals & Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of J. B. Chemicals & Pharmaceuticals Limited ("the Company"), for the quarter and nine months ended December 31, 2019 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), which has been initialed by us for the purpose of identification.
2. The Statement, which is the responsibility of the Company's management and approved by the Board of Directors in their respective meeting held on February 4, 2020, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted and procedure performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and management principles laid down in aforesaid Indian Accounting Standard ("Ind AS") and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D N V & Co

Firm Registration No.: 102079W

Chartered Accountants

Bharat



CA Bharat Jain

Partner

Membership No.: 100583

UDIN No: 20100583AAAABL2434

Place: Mumbai

Date: February 4, 2020



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2019

Sl.No.	PART I - Particulars	Quarter ended			Nine Month ended		(Rs. in lakhs)
		12/31/2019	9/30/2019	12/31/2018	12/31/2019	12/31/2018	Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	38,495.45	42,812.42	35,192.83	122,387.92	112,203.93	150,118.70
2	Other Income	1,602.19	1,810.70	1,557.92	4,646.64	2,493.65	4,022.50
3	Total Income (1+2)	40,097.64	44,623.12	36,750.75	127,034.56	114,697.58	154,141.20
4	Expenses						
a.	Cost of materials consumed	9,926.20	10,619.99	11,049.81	33,163.93	33,601.07	45,375.37
b.	Purchases of stock-in-trade	2,818.88	4,497.95	2,346.28	8,682.24	7,723.59	10,426.13
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	116.46	176.96	(1,964.69)	1,299.85	(2,263.92)	(2,165.74)
d.	Employee benefit expenses	7,355.40	6,969.05	6,475.90	21,388.56	19,039.62	25,797.86
e.	Finance Costs	85.28	87.43	126.93	253.08	325.73	411.51
f.	Depreciation and amortization expense	1,654.59	1,622.32	1,448.54	4,839.82	4,341.68	5,482.49
g.	Other Expenses	9,870.20	10,471.86	10,042.28	30,142.94	31,251.70	41,886.05
	Total Expenses (4)	31,827.01	34,445.56	29,525.05	99,770.42	94,019.47	127,213.67
5	Profit before Tax (3-4)	8,270.63	10,177.56	7,225.70	27,264.14	20,678.11	26,927.53
6	Tax expenses	2,053.37	581.63	2,588.35	5,536.31	6,689.70	8,721.61
7	Net Profit after Tax for the period (5-6)	6,217.26	9,595.93	4,637.35	21,727.83	13,988.41	18,205.92
8	Other Comprehensive Income (net of Tax)	(7.63)	(252.80)	(61.80)	(265.63)	(185.41)	29.25
9	Total Comprehensive Income after Tax (7+8)	6,209.63	9,343.13	4,575.55	21,462.20	13,803.00	18,235.17
10	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	7.75	11.96	5.64	27.08	17.02	22.15
	(2) Diluted	7.75	11.96	5.64	27.08	17.02	22.15

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 4, 2020.
- The auditors have carried out limited review of the financial results for the quarter and nine months ended December 31, 2019 and their report does not contain any qualification.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Company has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the standalone financial results for the quarter and nine months ended December 31, 2019, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and nine months ended December 31, 2019 is not material. To this extent, performance for the quarter and nine months ended December 31, 2019 is not comparable with previous period results.
- The Company has completed the buy-back of 29,54,545 equity shares of Rs. 2 each @ Rs. 440 per share on January 8, 2020. Post this buy-back, the share capital of the Company stands reduced to Rs. 15,45,64,194 divided into 7,72,82,097 equity shares of Rs. 2 each.
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

S. B. Mody

S.B.Mody
Whole time Director (Marketing)

Place : Mumbai
Date : 04/02/2020



Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2019

Sl.No.	PART I - Particulars	Quarter ended			Nine Month ended		(Rs. in lakhs)
		12/31/2019	9/30/2019	12/31/2018	12/31/2019	12/31/2018	Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	3/31/2019 Audited
1	Revenue from Operations	42,863.25	45,641.70	38,202.62	133,115.98	122,428.49	164,320.04
2	Other Income	1,637.96	1,850.85	1,582.03	4,749.61	2,578.90	4,143.99
3	Total Income (1+2)	44,501.21	47,492.55	39,784.65	137,865.59	125,007.39	168,464.03
4	Expenses						
	a. Cost of materials consumed	9,970.78	10,582.95	11,049.81	33,171.47	33,601.07	45,375.37
	b. Purchases of stock-in-trade	5,403.09	6,190.59	3,490.22	14,690.65	12,380.45	16,209.91
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(339.09)	(102.98)	(1,901.18)	518.08	(2,732.68)	(1,939.38)
	d. Employee benefit expenses	8,231.58	7,702.17	7,225.87	23,739.16	21,347.37	28,817.59
	e. Finance Costs	85.32	87.39	129.70	253.08	334.02	419.81
	f. Depreciation and amortization expense	1,674.86	1,638.65	1,466.01	4,893.30	4,404.17	5,564.20
	g. Other Expenses	10,637.27	11,242.85	10,540.15	32,412.97	33,802.03	45,317.27
	Total Expenses (4)	35,663.81	37,341.62	32,000.58	109,678.71	103,136.43	139,764.77
5	Profit before Tax (3-4)	8,837.40	10,150.93	7,784.07	28,186.88	21,870.96	28,699.26
6	Tax expenses	2,192.72	774.62	2,788.94	5,954.76	7,153.02	9,302.29
7	Net Profit after Tax for the period (5-6)	6,644.68	9,376.31	4,995.13	22,232.12	14,717.94	19,396.97
8	Other Comprehensive Income (net of Tax)	696.45	(572.27)	(631.48)	315.82	(695.84)	(419.64)
9	Total Comprehensive Income after Tax (7+8)	7,341.13	8,804.04	4,363.65	22,547.94	14,022.10	18,977.33
10	Net Profit after Tax for the period attributable to:						
	- owners of the company	6,627.72	9,362.41	4,985.49	22,190.78	14,680.92	19,346.63
	- non controlling interest	16.96	13.90	9.64	41.34	37.02	50.34
11	Other comprehensive income for the period attributable to:						
	- owners of the company	671.00	(548.54)	(626.32)	305.01	(650.11)	(372.44)
	- non controlling interest	25.45	(23.73)	(5.16)	10.81	(45.73)	(47.20)
12	Total Comprehensive Income after Tax attributable to:						
	- owners of the company	7,298.72	8,813.87	4,359.17	22,495.79	14,030.81	18,974.19
	- non controlling interest	42.41	(9.83)	4.48	52.15	(8.71)	3.14
13	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	8.26	11.67	6.07	27.66	17.86	23.54
	(2) Diluted	8.26	11.67	6.07	27.66	17.86	23.54

- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 4, 2020.
- The auditors have carried out limited review of the consolidated financial results for the quarter and nine months ended on December 31, 2019 and their report does not contain any qualification.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Group has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the consolidated financial results for the quarter and nine months ended December 31, 2019, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and nine months ended December 31, 2019 is not material. To this extent, performance for the quarter and nine months ended December 31, 2019 is not comparable with previous period results.
- The consolidated financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements.
- The Holding Company has completed the buy-back of 29,54,545 equity shares of Rs. 2 each @ Rs. 440 per share on January 8, 2020. Post this buy-back, the share capital of the Holding Company stands reduced to Rs. 15,45,64,194 divided into 7,72,82,097 equity shares of Rs. 2 each.
- The Group has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

S.B. Mody
Whole time Director (Marketing)

Place : Mumbai
Date : 04/02/2020

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

Independent Auditor's Review Report on Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2019 of the J. B. Chemicals and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
J. B. Chemicals and Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Holding Company") and its Subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2019 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('Listing Regulations'), which has been initialed by us for the purpose of identification. Attention is drawn to the fact that the consolidated figures for the corresponding quarter and nine months ended December 31, 2018 as reported in the unaudited consolidated financial results have been approved by the Holding Company's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors at its meeting held on February 4, 2020, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review of such consolidated financial statements.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following subsidiaries:

- i. 000 Unique Pharmaceutical Laboratories,
- ii. Unique Pharmaceutical Laboratories FZE and
- iii. Biotech Laboratories (Pty.) Ltd (Subsidiary of Unique Pharmaceutical Laboratories FZE)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes the interim financial information/ financial results of three subsidiaries which have not been reviewed by their auditors, whose interim financial information/ financial results reflect total revenue of Rs. 7,998.52 Lakhs and Rs.20,846.27 Lakhs, total net profit after tax of Rs. 385.33 Lakhs and Rs.1,100.61 Lakhs and total comprehensive income of Rs. 385.33 Lakhs and Rs.1,100.61 Lakhs for the quarter and nine months ended December 31, 2019 respectively, as considered in the Statement. These unaudited financial information/ financial results have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited financial information/ financial results. According to the information and explanations given to us by the Management, financials of these subsidiaries does not constitute significant component of the group's financial in accordance with circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Our conclusion on the Statement in respect of matter stated above is not modified with respect to our reliance on the financial results / financial information certified by the management.

For D N V & Co.
Chartered Accountants

Firm Registration No 102079W



CA Bharat Jain
Partner

Membership No: 100583

UDIN No: 20100583AAAABM2412



Place: Mumbai

Date: February 4, 2020



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2019

Sl.No.	PART I - Particulars	(Rs. in lakhs)					
		Quarter ended			Nine Month ended		Year ended
		12/31/2019	9/30/2019	12/31/2018	12/31/2019	12/31/2018	3/31/2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	42,863.25	45,641.70	38,202.62	133,115.98	122,428.49	164,320.04
2	Other Income	1,637.96	1,850.85	1,582.03	4,749.61	2,578.90	4,143.99
3	Total Income (1+2)	44,501.21	47,492.55	39,784.65	137,865.59	125,007.39	168,464.03
4	Expenses						
a.	Cost of materials consumed	9,970.78	10,582.95	11,049.81	33,171.47	33,601.07	45,375.37
b.	Purchases of stock-in-trade	5,403.09	6,190.59	3,490.22	14,690.65	12,380.45	16,209.91
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(339.09)	(102.98)	(1,901.18)	518.08	(2,732.68)	(1,939.38)
d.	Employee benefit expenses	8,231.58	7,702.17	7,225.87	23,739.16	21,347.37	28,817.59
e.	Finance Costs	85.32	87.39	129.70	253.08	334.02	419.81
f.	Depreciation and amortization expense	1,674.86	1,638.65	1,466.01	4,893.30	4,404.17	5,564.20
g.	Other Expenses	10,637.27	11,242.85	10,540.15	32,412.97	33,802.03	45,317.27
	Total Expenses (4)	35,663.81	37,341.62	32,000.58	109,678.71	103,136.43	139,764.77
5	Profit before Tax (3-4)	8,837.40	10,150.93	7,784.07	28,186.88	21,870.96	28,699.26
6	Tax expenses	2,192.72	774.62	2,788.94	5,954.76	7,153.02	9,302.29
7	Net Profit after Tax for the period (5-6)	6,644.68	9,376.31	4,995.13	22,232.12	14,717.94	19,396.97
8	Other Comprehensive Income (net of Tax)	696.45	(572.27)	(631.48)	315.82	(695.84)	(419.64)
9	Total Comprehensive Income after Tax (7+8)	7,341.13	8,804.04	4,363.65	22,547.94	14,022.10	18,977.33
10	Net Profit after Tax for the period attributable to:						
	- owners of the company	6,627.72	9,362.41	4,985.49	22,190.78	14,680.92	19,346.63
	- non controlling interest	16.96	13.90	9.64	41.34	37.02	50.34
11	Other comprehensive income for the period attributable to:						
	- owners of the company	671.00	(548.54)	(626.32)	305.01	(650.11)	(372.44)
	- non controlling interest	25.45	(23.73)	(5.16)	10.81	(45.73)	(47.20)
12	Total Comprehensive Income after Tax attributable to:						
	- owners of the company	7,298.72	8,813.87	4,359.17	22,495.79	14,030.81	18,974.19
	- non controlling interest	42.41	(9.83)	4.48	52.15	(8.71)	3.14
13	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	8.26	11.67	6.07	27.66	17.86	23.54
	(2) Diluted	8.26	11.67	6.07	27.66	17.86	23.54

- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 4, 2020.
- The auditors have carried out limited review of the consolidated financial results for the quarter and nine months ended on December 31, 2019 and their report does not contain any qualification.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Group has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the consolidated financial results for the quarter and nine months ended December 31, 2019, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and nine months ended December 31, 2019 is not material. To this extent, performance for the quarter and nine months ended December 31, 2019 is not comparable with previous period results.
- The consolidated financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements.
- The Holding Company has completed the buy-back of 29,54,545 equity shares of Rs. 2 each @ Rs. 440 per share on January 8, 2020. Post this buy-back, the share capital of the Holding Company stands reduced to Rs. 15,45,64,194 divided into 7,72,82,097 equity shares of Rs. 2 each.
- The Group has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

S.B. Mody
Whole time Director (Marketing)



Place : Mumbai
Date : 04/02/2020

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380